Spero Therapeutics (SPRO) Expected to Post Quarterly Earnings on Tuesday

Spero Therapeutics (NASDAQ:SPRO) is projected to release its Q2 2026 results after the market closes on Tuesday, August 11th. Analysts expect Spero Therapeutics to post earnings of ($0.17) per share and revenue of $0.2820 million for the quarter. Interested persons can check the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Tuesday, August 11, 2026 at 4:30 PM ET.

Spero Therapeutics (NASDAQ:SPRO) last released its quarterly earnings data on Wednesday, May 13th. The company reported ($0.13) EPS for the quarter, beating analysts’ consensus estimates of ($0.18) by $0.05. The firm had revenue of $0.26 million for the quarter, compared to analysts’ expectations of $0.26 million. Spero Therapeutics had a return on equity of 35.58% and a net margin of 24.90%.

Spero Therapeutics Trading Up 4.3%

Spero Therapeutics stock traded up $0.05 during mid-day trading on Tuesday, hitting $1.20. The company’s stock had a trading volume of 302,463 shares, compared to its average volume of 882,862. The firm has a market capitalization of $69.48 million, a PE ratio of 5.00 and a beta of 1.55. Spero Therapeutics has a 1 year low of $1.08 and a 1 year high of $3.08. The stock’s fifty day moving average is $2.13 and its two-hundred day moving average is $2.35.

Analysts Set New Price Targets

Several equities analysts have recently commented on the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Spero Therapeutics in a research note on Friday, July 17th. Wall Street Zen lowered shares of Spero Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Saturday, May 16th. One equities research analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Reduce”.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the company. GSK plc purchased a new position in shares of Spero Therapeutics during the fourth quarter worth $21,414,000. Vanguard Group Inc. boosted its holdings in Spero Therapeutics by 2.0% during the 3rd quarter. Vanguard Group Inc. now owns 1,989,855 shares of the company’s stock valued at $3,741,000 after acquiring an additional 39,474 shares during the period. State Street Corp boosted its holdings in Spero Therapeutics by 10.1% during the 4th quarter. State Street Corp now owns 210,151 shares of the company’s stock valued at $490,000 after acquiring an additional 19,200 shares during the period. Arrowstreet Capital Limited Partnership acquired a new position in Spero Therapeutics in the 3rd quarter valued at about $283,000. Finally, OMERS ADMINISTRATION Corp acquired a new position in Spero Therapeutics in the 4th quarter valued at about $306,000. 25.60% of the stock is currently owned by institutional investors and hedge funds.

Spero Therapeutics Company Profile

Spero Therapeutics is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel therapies to address multidrug‐resistant bacterial infections. Headquartered in Boston, Massachusetts, the company aims to advance a pipeline of oral and intravenous antibiotic candidates designed to treat serious infectious diseases that pose significant public health challenges.

The company’s lead candidate, tebipenem HBr, is an oral carbapenem antibiotic being developed for the treatment of complicated urinary tract infections caused by resistant Gram‐negative pathogens.